Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - AccuredShares IssuedShares OutstandingShares Outstanding
Ratios

SAB Biotherapeutics (SABS) Other Gross PP&E Adjustments (2020 - 2026)

SAB Biotherapeutics filings provide 7 years of Other Gross PP&E Adjustments readings, the most recent being $28.5 million for Q1 2026.

  • On a quarterly basis, Other Gross PP&E Adjustments rose 7.92% to $28.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $28.5 million, a 7.92% increase, with the full-year FY2025 number at $24.2 million, down 7.19% from a year prior.
  • Other Gross PP&E Adjustments hit $28.5 million in Q1 2026 for SAB Biotherapeutics, up from $24.2 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $28.7 million in Q1 2024 to a low of -$1.0 million in Q2 2022.
  • Median Other Gross PP&E Adjustments over the past 5 years was $26.2 million (2024), compared with a mean of $23.6 million.
  • Biggest five-year swings in Other Gross PP&E Adjustments: soared 2857.96% in 2023 and later decreased 8.36% in 2024.
  • SAB Biotherapeutics' Other Gross PP&E Adjustments stood at $23.8 million in 2022, then rose by 9.66% to $26.1 million in 2023, then decreased by 0.0% to $26.1 million in 2024, then fell by 7.19% to $24.2 million in 2025, then rose by 17.68% to $28.5 million in 2026.
  • The last three reported values for Other Gross PP&E Adjustments were $28.5 million (Q1 2026), $24.2 million (Q4 2025), and $27.1 million (Q3 2025) per Business Quant data.